About Naronapride (ATI-7505)

We have generated positive data in four Phase 2 clinical trials of naronapride for the treatment of multiple gastrointestinal disorders, including gastroparesis, chronic idiopathic constipation (CIC), gastro-esophageal reflux disease (GERD), and erosive esophagitis (EE).
​
Naronapride is currently in development for two upper GI indications:

• Gastroparesis 
  • Phase 2b trial in Europe and USA for gastroparesis, with our partner Dr. Falk Pharma GmbH.
• PPI non-responsive symptomatic GERD (PPI-nrsGERD)
  • Clinical trials are due to commence in the US in H1 2026.